




(86) Date de dépôt PCT/PCT Filing Date: 2003/08/21
(87) Date publication PCT/PCT Publication Date: 2004/03/11
(85) Entrée phase nationale/National Entry: 2005/02/22
(86) N° demande PCT/PCT Application No.: US 2003/026008
(87) N° publication PCT/PCT Publication No.: 2004/019822
(30) Priorité/Priority: 2002/08/31 (10/232,774) US

(51) Cl.Int.⁷/Int.Cl.⁷ A61F 2/06
(71) Demandeur/Applicant:
BOSTON SCIENTIFIC LIMITED, BB
(72) Inventeurs/Inventors:
SCHEUERMANN, TORSTEN, DE;
ALT, ECKHARD, DE
(74) Agent: SMART & BIGGAR


(54) Titre : STENT CONSTITUE DE NIOBIUM

(54) Title: NIOBIUM STENT



(57) Abrégé/Abstract:

In a process of fabricating a stent composed primarily of niobium alloyed with a trace amount of zirconium, tantalum, or titanium for hardening, the stent is annealed under vacuum in a substantially oxygen-free environment. The vacuum is preferably maintained at pressure less than 10^{-4} millibars, oxygen-content less than about 80 parts per million, and the annealing temperature exceeds 400°C for at least one hour, and is preferably kept in a range from about $1100\text{-}1200^{\circ}\text{C}$ for several hours. This may be followed by applying a surface layer of oxide, such as iridium oxide, with a thickness of 299-300 nm to the stent.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 March 2004 (11.03.2004)

PCT

(10) International Publication Number
WO 2004/019822 A1

(51) International Patent Classification⁷: **A61F 2/06**

(21) International Application Number:
PCT/US2003/026008

(22) International Filing Date: 21 August 2003 (21.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/232,774 31 August 2002 (31.08.2002) US

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: **INFLOW DYNAMICS INC.** [US/US];
P.O.Box 1247, Springfield, VA 22151 (US).

Published:
— with international search report

(72) Inventors: **SCHEUERMANN, Torsten**; Viktor-Scheffel-Str. 20, 80803 Munich (DE). **ALT, Eckhard**; Eichendorff-strasse 52, 85521 Ottobrunn (DE).

(48) Date of publication of this corrected version:
29 April 2004


(74) Agent: **Nguyen, Tu, N.**; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110 (US).

(15) Information about Correction:
see PCT Gazette No. 18/2004 of 29 April 2004, Section II

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NIOBIUM STENT



(57) Abstract: In a process of fabricating a stent composed primarily of niobium alloyed with a trace amount of zirconium, tantalum, or titanium for hardening, the stent is annealed under vacuum in a substantially oxygen-free environment. The vacuum is preferably maintained at pressure less than 10^{-4} millibars, oxygen-content less than about 80 parts per million, and the annealing temperature exceeds 400°C for at least one hour, and is preferably kept in a range from about $1100\text{--}1200^{\circ}\text{C}$ for several hours. This may be followed by applying a surface layer of oxide, such as iridium oxide, with a thickness of 299-300 nm to the stent.

WO 2004/019822 A1

NIOBIUM STENT

Cross-Reference to Related Applications

This application is a continuation-in-part of co-pending patent application Serial
5 No. 09/663,896, filed September 18, 2000 ("the '896 application"), and is further related to
co-pending patent application Serial No. 09/634,667, filed August 8, 2000 ("the '667
application"), both of the same assignee as the present application.

Background of the Invention

10 The present invention relates generally to stents that are implantable or deployable
in a vessel or duct within the body of a patient to maintain the lumen of the duct or vessel
open, and more particularly to improvements in stent structures.

When inserted and deployed in a vessel, duct or tract of the body, for example a
coronary artery after dilatation of the artery by balloon angioplasty, a stent acts as a
15 prosthesis to maintain the vessel, duct or tract (generally referred to as a vessel for
convenience herein) open. The stent has the form of an open-ended tubular element with
openings through its sidewall to enable its expansion from a first outside diameter which is
sufficiently small to allow it to be navigated through the vessel to a target site where it is to
be deployed, to a deployed second outside diameter sufficiently large to engage the inner
20 lining of the vessel for retention at the target site.

An occluded coronary artery, for example, is typically attributable to a buildup of
fatty deposits or plaque on the inner lining of the vessel. A balloon angioplasty procedure
is the treatment of choice to compress the deposits against the inner lining of the vessel to
open the lumen. Alternatively, removal of plaque may be achieved by laser angioplasty, or

by rotationally cutting the material into finely divided particles which are dispersed in the blood stream. For a large segment of patients undergoing the procedure, traditional angioplasty has resulted in new blockage of the treated vessel only a relatively short time thereafter, attributable to trauma to the blood vessel wall from the original procedure. The
5 mechanism responsible for this restenosis or re-occlusion of the vessel lumen is intimal hyperplasia, a rapid proliferation of smooth muscle cells in the affected region of the wall.

To maintain the vessel open, it has become customary to install a stent at the trauma site at the time of or shortly after the angioplasty procedure is performed. The stent is deployed by radial expansion under outwardly directed radial pressure exerted, for
10 example, by active inflation of a balloon of a balloon catheter on which the stent is mounted. In some instances, passive spring characteristics of a pre-formed elastic (i.e., self-opening) stent serves the purpose. The stent is thus expanded to engage the inner lining or inwardly facing surface of the vessel wall with sufficient resilience to allow some contraction but also with sufficient stiffness to largely resist the natural recoil of the vessel
15 wall.

The presence of the stent in the vessel, however, tends to promote thrombus formation as blood flows through the vessel, which results in an acute blockage. The thrombosis and clotting may be reduced or even eliminated by appropriate surface characteristics of the stent, sufficient to achieve this purpose. At the outward facing
20 surface of the stent in contact or engagement with the inner lining of the vessel, tissue irritation can exacerbate restenosis attributable to hyperplasia.

Another factor affecting the choice of the stent and the stent material is allergic

reaction to common stent materials suffered by a statistically significant percentage of the patient population subjected to stenting. These materials include chrome, nickel, and medical grade 316L stainless steel, which contains about 16% nickel. For such patients, the allergic reaction may be sufficient that stent implant is contraindicated. Wholly
5 biodegradable stents of possibly sufficient radial strength are currently undergoing tests and may prove suitable in such cases.

Another consideration in material selection is the need for the implanting physician to be able to visualize the position of the stent during implantation to the desired target site in the body, and for purposes of examination from time to time thereafter at the implant
10 site, typically by x-ray fluoroscopy. The wall of the stent must be sufficiently thick, depending on the stent material, not only to withstand the vessel wall recoil that invariably follows deployment at the target site, but to allow the stent to be seen on the fluoroscope. Various materials, such as 316L stainless steel, possess suitable mechanical strength. Typical stent wall or wire thicknesses have ranged from 70 to 200 microns (or
15 micrometers, μm). A 70 to 80 μm thick 316L steel stent offers sufficient strength to resist recoil so as to maintain a lumen diameter close to the diameter achieved at full deployment by balloon inflation. This relatively thin and tiny metal structure creates little shadow on a fluoroscopic picture, however, since the x-ray absorption of the metal is low. Increasing the wall thickness of the stent to enhance its radiopacity and recoil resistance makes the
20 stent less flexible, however, which adversely affects its maneuverability through narrow vessels and the amount of balloon pressurization necessary to enlarge the stent diameter sufficiently during deployment, with concomitant increased risk of balloon rupture.

It follows that a suitable stent for successful interventional placement should possess features of relatively non-allergenic reaction, good radiopacity, freedom from distortion on magnetic resonance imaging (MRI), flexibility with suitable elasticity to be plastically deformable, resistance to vessel recoil, sufficient thinness to minimize
5 obstruction to flow of blood (or other fluid or material in vessels other than the cardiovascular system), and biocompatibility to avoid of vessel re-occlusion. Selection of the stent material, as well as design of the stent, plays an important role in influencing these features.

Aside from vascular usage, other ducts or tracts of the human body in which a stent
10 might be installed to maintain an open lumen include the tracheo-bronchial system, the biliary hepatic system, the esophageal bowel system, and the urinary tract. Many of the same requirements are found in these other endoluminal usages of stents.

Despite improvements in the design and construction of coronary stents, restenosis remains a problem. A major contributing factor is the inability of the body to incorporate
15 the implanted foreign material quickly. Basic research with cell cultures and animal experiments have demonstrated that the degree of endothelialization of the foreign body determines the amount of the restenosis. It has been an assumption among industry practitioners and researchers that a highly polished and smooth surface is beneficial to prevent stent thrombosis and to facilitate endothelialization, but experiments indicate this
20 may not be entirely true.

A significant reason for the lack of a high clinical success rate with electropolished stents is the fact that the smooth muscle cells which seek to envelop a foreign body, such

as a stent strut into the vessel wall, require a higher degree of proliferation to cover the foreign body. The continuing flow of blood with a high pressure and high shearing stress prevents the migration of smooth muscle cells, which proliferate from the media and adventitial cells of a stented vessel such as a coronary artery. It has been shown that a slightly rough surface considerably facilitates the coverage by smooth muscle cells, leading to a functional endothelial layer even after 10 to 14 days after stent implantation. A single layer of endothelial cells has been found to seal the neointima and thereby prevent the stimulus which facilitates and enhances the proliferation of cells beyond mere coverage of the foreign body.

The thinner the stent strut, the less the lumen of the stented vessel is obstructed. Moreover, a thin stent is more easily covered by a neoendothelial build-up. Accordingly, it is desirable to make the stent wall as thin as can be practically achieved. But the fluoroscopic visibility of stainless steel, for example, in a thickness below 60 μm is very poor because of the limited extinction of x-rays by such a thin metal tube.

Some improvement has been achieved by applying a suitable adherent material layer to stent core material of medical grade implantable 316L stainless steel. Layer materials have included gold and certain other noble metals, such as platinum. Such materials typically exhibit much greater radiopacity than stainless steel, that renders the stent highly visible under fluoroscopy as it is being advanced through the vessel lumen to the desired site of deployment, as well as after deployment. They are also substantially non-allergenic and non-thrombogenic. Such coating may be provided in a very thin layer, so the stent wall thickness is determined almost solely by considerations of mechanical

strength. Coatings, however, present a need for absolute adherence to the underlying metal of the stent to avoid cracking or defects in the homogeneous overlying layer, and sufficient resistance to peeling or flaking of the layer during insertion, and especially during expansion of the diameter of the stent as it is being deployed in final position in the artery
5 at the target site, objectives which are not easily achievable.

The disadvantage of reduced mechanical strength of noble metals such as gold or platinum -- which makes them unsuitable if sought to be used alone for application in the human vascular system -- is overcome by the use of a core composed of a material such as stainless steel, having considerably better mechanical properties than the noble metal. But
10 the presence of cracks or related defects in the surface coating can produce a galvanic potential which could ultimately lead to corrosion of the underlying steel or lesser metal, an unacceptable situation for a device intended to be permanently implanted in the body. Therefore, manufacturing requires a high degree of quality control and concomitant high cost.

15 Alternative or additional layers have also been used in stents. Applicant's U.S. Patent No. (USPN) 6,099,561 discloses a stent structure having three fundamental layers, a first underlying layer of a base metal that functions to provide high mechanical strength, a second intermediate layer that functions to provide high fluoroscopic visibility -- preferably a noble metal layer or alloy thereof --, and a top layer of a particularly beneficial
20 biocompatible material -- preferably a ceramic-like material such as iridium oxide or titanium nitrate. The intermediate layer of elemental or alloy of a noble metal is uninterrupted, highly adherent for tight coverage and substantially uniform thickness.

Such an intermediate layer tends to assure avoidance of a galvanic potential that would lead to corrosion of the lesser, base metal, including such a condition that may obtain with a layer of ceramic-like metal overlying the base metal at points where fissures might exist were it not for the uninterrupted presence of the intermediate noble metal layer. The 3-
5 layer stent of the '561 patent exhibits mechanical strength, small physical dimensions, increased visibility, long-term stability, and a highly biocompatible surface that enables rapid endothelialization with low occurrence of restenosis.

The '896 application, of which the present application is a continuation-in-part, discloses a stent adapted to be expanded from a first vessel-navigable diameter to a larger
10 second vessel-deployed diameter, which is composed of material that possesses all of the desirable attributes mentioned above and yet can be fabricated in a single homogeneous structure without need for additional layers. The stent material is niobium, preferably with a sufficient amount of zirconium added, typically less than 5% by weight, for hardness of the combination. The stent may thus be fabricated from a single piece of tubing at
15 relatively low cost and yet with all of the desirable features of non-allergenic reaction, excellent and adequate radiopacity (density twice that of stainless steel), distortionless for MRI, highly flexible, sufficiently elastic to be plastically deformable, non-brittle, sufficient strength to resist vessel recoil, and sufficient thinness to minimize obstruction to blood flow, and highly biocompatible. The niobium/zirconium material is anodized to provide
20 surface oxidation. This material is readily treatable by post-processing such as annealing, electro-polishing for rounded edges, and so forth.

Additional surface modification or other substances or agents may be applied to the

stent surface, such as vapor deposition of even more highly biocompatible layers, to preclude occlusion from restenosis or thrombosis during the acute stage following deployment of the stent. For example, iridium and iridium oxide, titanium nitrate, or compositions such as described in USPN 5,679,815, might be applied.

5 The stent may also be formed from a sintering process with small microspheres by heat and pressure (e.g., such as disclosed in USPN 5,198,187), thereby avoiding costly production and control steps.

Summary of the Invention

10 Applicant has found that a stent composed primarily of niobium alloyed with a trace amount (e.g., less than 5% by weight, preferably about 1%) of preferably zirconium, but alternatively tantalum or titanium, or additive material such as described in USPNs 5,472,794 and 5,679,815, exhibits considerably improved performance structurally, e.g., to avoid brittleness and thrombogenicity, if the completed stent is annealed post-fabrication
15 in a substantially oxygen-free atmosphere. The latter should be an extreme vacuum environment of from 10^{-4} to 10^{-6} millibars (mbar) pressure, preferably 10^{-5} mbar or less vacuum pressure, with less than about 80 parts per million (ppm) of O_2 , at an annealing temperature exceeding $400^{\circ}C$, preferably about $1200^{\circ}C$, for several hours, nominally more than one hour. O_2 and H_2 content of the stent material should be kept at low levels.

20 A surface layer of oxide, such as iridium oxide, may be applied as a post-annealing step by anodizing or sputtering, for example, to a thickness of, say, 200-300 nanometers (nm). Oxygen content of the material is kept within the specified bounds by wrapping the stent in an O_2 -gathering tantalum foil.

Brief Description of the Drawing

The above and still further aims, objectives, features, aspects and attendant advantages of the present invention will become apparent to those skilled in the art from the following detailed description of a best mode presently contemplated of practicing the invention by reference to certain preferred embodiments and methods of manufacture thereof, taken in conjunction with the sole Figure of drawing which shows a side view of a preferred stent structure for the invention (in which the far side is not shown for the sake of simplicity).

Detailed Description of the Best Mode of Practicing the Invention

The sole Figure is a perspective view (not to scale) of a stent 10 in the form of a hollow tubular self-supporting structure composed primarily of niobium (Nb), with a trace amount of zirconium (Zr), titanium (Ti) or tantalum (Ta) for example, preferably zirconium, the trace amount preferably less than 5%, more preferably approximately 1%, and remainder niobium. The added trace metal improves physical characteristics of the stent for its intended function. Typically, the stent material used by applicant also has negligible amounts of tantalum (Ta, about 180 micrograms per gram ($\mu\text{g/g}$)), iron (Fe, $< 20 \mu\text{g/g}$), silicon (Si, about $< \mu\text{g/g}$), tungsten (W, $< 20 \mu\text{g/g}$), nickel (Ni, $< 20 \mu\text{g/g}$), molybdenum (Mo, $< 20 \mu\text{g/g}$), hafnium (Hf, $< 20 \mu\text{g/g}$), carbon (C, about $7 \mu\text{g/g}$), and nitrogen (N, about $53 \mu\text{g/g}$), as well as amounts of hydrogen (H) and oxygen (O) primarily introduced during the processing.

Important values of these minor elemental constituents are those of O_2 and H_2 .

Both of these elements tend to increase brittleness of the stent material dramatically if their values too high. Chemical finishing (H₂ source) and the vacuum annealing (O₂ source) steps of applicant's process are intentionally set to keep the value of H at less than 10 ppm and the value of O at less than 80 ppm to prevent brittleness, with a desire to keep the O
5 content at less than about 35 µg/g.

The presently preferred process of fabricating the stent is performed in the following sequence of steps: (1) tube processing from Nb-1%Zr ingots; (2) laser cutting of tube; (3) mechanical and chemical finishing; (4) electropolishing; (5) vacuum annealing; and (6) anodizing or sputtering with surface coating, preferably iridium oxide. Anodizing
10 or sputtering of iridium oxide ("Irox") before vacuum annealing will increase the O₂ amount in the core material, so the Irox is preferably applied after annealing and, additionally, excess oxygen content is avoided by a technique to be described presently herein.

In the laser cutting process, the tubular stent member is provided with a multiplicity
15 of through-holes or openings 12 through sidewall 15, defined and bounded by a plurality of struts or links 13, which enables expansion of the stent diameter when the device is to be deployed at a target site in a vessel, duct or tract of the human body. The openings 12 may be precisely cut out to form a latticework sidewall using a narrow laser beam of a conventional laser that follows a programmable pattern. The removed material that
20 formerly occupied openings 12 is discarded following the cutting.

For example, the resulting pattern in the latticework sidewall 15 is a network of interconnected struts 13 which are optimized for orientation predominantly parallel to the

longitudinal axis 16 of the tube 11, with none of the struts oriented perpendicular (i.e., transverse) to the axis 16, so that no strut interconnecting any other struts in the latticework is oriented to lie completely in a plane transverse to the longitudinal axis, without running from one end of the stent to the opposite end. This type of structure, which is described in
5 detail in applicant's USPN 6,398,805, provides a relatively very low friction characteristic (or coefficient of friction) of the outer surface 17 of the stent, to ease advancement of stent 10 in a vessel, duct or tract to a site for deployment. The network or latticework of struts 13 may define a series of longitudinally repeating circumferential rows 20 of openings 12, in which each opening has a shape which resembles the outline of a handlebar moustache, or of a Dutch winged cap, with each opening bounded by alternating links in wavelets of
10 higher and lower crests in successive rows of each circumferential column displaced along the length of the cylindrical element. If viewed upside down, the openings have a shape resembling the outline of a ram's head with horns projecting at either side upwardly from the head and then downwardly, each opening bounded by alternating links in wavelets of
15 shallower and deeper troughs in successive rows of each circumferential column displaced along the length of the cylindrical element.

Each pair of struts such as 21, 22 bounding an opening 12 in any given row 25 are in the shape of circumferentially displaced wavelets with adjacent circumferentially aligned higher and lower crests 26, 27, respectively, in which the wavelets intersect (30)
20 one another at one or both sides of the crests (30, 31). The intersection 30 of struts (or wavelets) at one side of the adjacent circumferentially aligned crests 26, 27 of row 25 is tangential to a crest 33 of the immediately adjacent row 35, and the intersection 31 of struts

(or wavelets) at the other side of those crests is tangential to a crest 37 of the immediately adjacent row 38. Interconnecting points such as 40 between the struts may be notched to enhance symmetrical radial expansion of the stent during deployment thereof.

When the stent 10 is crimped onto a small diameter (low profile) delivery balloon
5 (not shown), the adjacent circumferentially aligned crests of each row move closer together, and these portions will then fit into each other, as the pattern formed by the latticework of struts allows substantial nesting together of the crests and bows, which assures a relatively small circumference of the stent in the crimped condition. Such a stent is highly flexible, and is capable of undergoing bending to a small radius corresponding to
10 radii of particularly tortuous coronary arteries encountered in some individuals, without permanent plastic deformation.

As the stent 10 is partially opened by inflation of the balloon during deployment, the adjacent crests begin to separate and the angle of division between struts begins to open. When the stent is fully expanded to its deployed diameter, the latticework of struts
15 takes on a shape in which adjacent crests undergo wide separation, and portions of the struts take on a transverse, almost fully lateral orientation relative to the longitudinal axis of the stent. Such lateral orientation of a plurality of the struts enables each fully opened cell to contribute to the firm mechanical support offered by the stent in its fully deployed condition, to assure a rigid structure which is highly resistant to recoil of the vessel wall
20 following stent deployment. The particular configuration of the stent structure, while highly desirable, is illustrative only.

The stent may be pre-opened after fabrication to relieve stresses. Pre-opening

produces a stent inner diameter that allows the stent to slide comfortably over the uninflated mounting balloon, for ease of crimping the stent onto the balloon. Annealing may be performed after pre-opening by heating the stent structure to an appropriate temperature for a predetermined interval of time.

5 The niobium/zirconium material of the stent is fabricated in any conventional manner for producing alloys, with the zirconium amounting from 1% to 5% by weight, preferably about 2%, and the remainder niobium. For example, the manufacturing process may be performed by sintering particles or microspheres of the constituent metals under heat and pressure. Rather than using zirconium as the trace metal, a trace amount (e.g.,
10 one to three percent) of titanium or tantalum may be alloyed with the niobium for added strength and other desirable physical characteristics. Other suitable alternative additive materials include those described in USPNs 5,472,794 and 5,679,815, for example. The alloy is then formed into tubing and the through holes are provided in its side wall as described above.

15 According to the process aspect of the present invention, the principally niobium stent exhibits much improved performance structurally, with improved resistance against brittleness and thrombogenicity, by annealing the completed structure post-fabrication in a substantially oxygen-free atmosphere. Preferably, the environment is one of an extreme vacuum ranging from about 10^{-5} to about 10^{-6} millibars pressure, with less than about 80
20 parts per million (ppm) of O_2 . The annealing is performed at a temperature greater than $400^{\circ}C$, preferably at about $1100-1200^{\circ}C$ for at least one hour, and more preferably for several hours.

The stent structure can be produced with a wall thickness of about 85 μm , which offers sufficient mechanical strength to resist the natural recoil of the blood vessel wall following deployment of the stent, as well as excellent visibility under fluoroscopy, but which does not obstruct the vessel lumen to any significant extent. Since it has none of the distortion encountered with metallic 316L stents to MRI, use of the niobium-based stent in
5 noninvasive monitoring also of cerebral and peripheral vessels is highly beneficial.

The surface layer of iridium oxide is preferably applied post-annealing to avoid brittleness-producing oxygen contribution to the material. Surface modification of the stent to apply the preferred coating of iridium oxide, or alternatively, of titanium nitrate is
10 achieved by vapor deposition, plasma deposition, or other conventional method. Such modification may be used to give the stent a rough surface. Alternatively, the surface may be anodized for oxidation of the niobium to achieve reduced immunoresponse and less thrombogenicity.

The most critical portion of the process currently utilized by applicant as the best
15 mode for practicing that aspect of the invention is as follows:

1. Dissolve the natural oxide layer (< 2 nm thick) by placing stents for more than 1 minute in 10% hydrofluoric (HF) acid.
2. Wrap Nb-1%Zr stents loosely in tantalum foil gathering O_2 because of its high oxygen affinity, to further prevent undesirable contribution to oxygen content.
- 20 3. Introduce wrapped stents plus additional gather foil into recipient chamber.
4. Heat up in 5 hrs. to 600°C maintaining vacuum $< 10^{-4}$ mbar (preferably $< 10^{-5}$ mbar, but with recognition of considerably higher equipment cost).

5. Maintain temperature for about 2 hours.
6. Increase heating in 5 hours to 1120°C, maintaining vacuum $< 10^{-4}$ mbar.
7. Maintain set temperature for another 3 hours.
8. Cool down to 60°C while maintaining vacuum.
- 5 9. Remove stents and the O₂-gather foil from recipient chamber.

Although a best mode of practicing the invention has been disclosed by reference to a preferred method and embodiment, it will be apparent to those skilled in the art from a consideration of the foregoing description that variations and modifications may be made without departing from the spirit and scope of the invention. Accordingly, it is intended
10 that the invention be limited only by the appended claims and the rules and principles of applicable law.

What is claimed is:

1 **1.** In a process for fabricating a stent from a single homogeneous tubing
2 composed principally of niobium with a trace of additional metal for alloy formation and
3 reinforcement, the step of annealing the stent under vacuum in a substantially oxygen-free
4 environment.

1 **2.** The process of claim 1, wherein the trace metal is selected from a group
2 including zirconium, tantalum and titanium, and said trace is less than approximately 5%.

1 **3.** The process of claim 1, wherein said vacuum is in a range from about 10^{-4}
2 to about 10^{-6} millibars of pressure, with less than about 80 parts per million (ppm) of O_2 .

1 **4.** The process of claim 3, wherein said step of annealing is performed at a
2 temperature greater than $400^{\circ}C$, for at least one hour.

1 **5.** The process of claim 3, wherein said annealing is performed at a
2 temperature in a range of about $1100-1200^{\circ}C$, for several hours.

1 **6.** The process of claim 1, including a post-annealing step of at least partially
2 coating the stent surface with a material to inhibit closure of a central lumen at a site of
3 stent implant in the body.

1 7. The process of claim 6, wherein said surface coating step is performed by
2 vapor deposition or plasma deposition of said coating material.

1 8. The process of claim 6, wherein said coating material is iridium oxide.

1 9. The process of claim 6, wherein said coating material is titanium nitrate.

1 10. The process of claim 6, wherein said coating material is niobium oxide.

1 11. The process of claim 10, including forming said niobium oxide by
2 anodizing the stent surface.

1 12. The process of claim 1, including keeping the stent wrapped in a material
2 having affinity for oxygen during the stent processing under vacuum, to reduce oxygen
3 entry into the stent tubing.

1 13. A stent formed from a single homogeneous tube composed principally of
2 niobium with a trace of additional metal for alloy formation and reinforcement, the stent
3 composition having an oxygen content of less than about 35 micrograms per gram of stent.

1 14. The stent of claim 13, wherein the trace metal is selected from a group
2 including zirconium, tantalum and titanium, and said trace is less than approximately 5%.

1 **15.** The stent of claim 13, wherein the stent is annealed and the annealing was
2 performed in a substantially oxygen-free vacuum environment ranging from about 10^{-4} to
3 about 10^{-6} millibars of pressure.

1 **16.** The stent of claim 13, including an iridium oxide coating on the stent
2 surface.

1 **17.** The stent of claim 13, including a titanium nitrate coating on the stent
2 surface.

18. The stent of claim 13, including a niobium oxide coating on the stent
surface.

1/1




FIG. 1

